CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
Stock Information for Kandi Technologies Group Inc.
Loading
Please wait while we load your information from QuoteMedia.